Eagle Pharmaceuticals

EGRXPhase 3

Woodcliff Lake, United StatesFounded 2007eagleus.com

Eagle Pharmaceuticals is a NASDAQ-listed company (EGRX) headquartered in Woodcliff Lake, NJ, dedicated to developing innovative drugs that result in meaningful improvements in patients' lives. The company operates with a strategic focus on critical care and oncology, balancing a commercial-stage portfolio with a pipeline of novel product candidates. Eagle's mission is to bring brilliant science to life by serving patients, healthcare providers, and health systems, thereby creating value for all stakeholders.

Market Cap

$3.3M

-92.6% period

Pipeline

2 in Phase 3

Patents

—

Publications

—

EGRX · Stock Price

USD 0.091.06 (-92.61%)

Historical price data

AI Company Overview

Critical CareOncology

Technology Platform

Eagle focuses on developing novel formulations and new chemical entities (NCEs) to address unmet medical needs, leveraging expertise in pharmaceutical development and regulatory strategy rather than a single proprietary technological platform.

Pipeline

8 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
Arm 1 Cataract Surgery performed with remimazolam as sedativ...	Cataract Surgery Anesthesia	Approved
Placebo + Mesalamine + Mesalamine	Mild to Moderate Ulcerative Colitis	Phase 3
Ryanodex and Standard of Care	Exertional Heat Stroke	Phase 3
CAL02 + Placebo	Pneumonia, Bacterial	Phase 2
Ryanodex (dantrolene sodium) for injectable suspension	Drug Toxicity Psychotropic Agents Psychostimulants	Phase 2

Funding History

Total raised:$60M

IPO$60MUndisclosedFeb 6, 2014

Opportunities

Significant growth opportunities exist in advancing CAL02 for severe pneumonia, a large unmet need with Fast-Track designation, and in launching EA-114's optimized fulvestrant formulation in the substantial breast cancer market.

The agnostic respiratory stimulant ENA-001 also presents a multi-indication opportunity in critical care, supported by external funding.

Risk Factors

Key risks include clinical trial failures for lead pipeline assets (CAL02, ENA-001), regulatory setbacks for EA-114's NDA, intense competition in both critical care and oncology markets, and potential future capital needs that could dilute shareholders.

Competitive Landscape

Eagle competes with large pharma and generic companies in the sedation (BYFAVO) and oncology spaces. Its pipeline differentiates through novel mechanisms (CAL02's anti-toxin approach) and optimized formulations (EA-114), targeting specific gaps within large, established therapeutic markets rather than pursuing first-to-market blockbusters.